Corcept Therapeutics Faces Securities Class Action After Major Failures with FDA and Patent Lawsuit

Corcept Therapeutics Faces Securities Class Action Following Major Issues

In a major development that has caught the attention of the financial community, Corcept Therapeutics Incorporated (NASDAQ: CORT) is currently facing a class action lawsuit initiated by the national shareholder rights law firm, Hagens Berman. This legal action arises in the wake of the company's significant failures, particularly related to its interactions with the FDA and issues surrounding its drug candidate, relacorilant.

The Class Action Background

The lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., was filed in the U.S. District Court for the Northern District of California and seeks to hold the company accountable for what is alleged to be misleading information disseminated to investors. Investors who purchased or acquired Corcept common stock during the period from October 31, 2024, to December 30, 2025, are encouraged to come forward, especially as the deadline to move for Lead Plaintiff status is set for April 21, 2026.

Hagens Berman's partner Reed Kathrein emphasized the core issue of this case—an apparent 'information gap' between the company's public communications and the warnings it received from the FDA in private. This gap has left many investors questioning the integrity of the company’s disclosures about its drug pipeline, specifically surrounding relacorilant.

Allegations of Concealment

The allegations against Corcept particularly highlight that management had concealed crucial warnings from the FDA regarding the inadequacy of data supporting the efficacy of relacorilant. Reports indicate that in meetings with the FDA, the company received stark warnings that the data lacked sufficient evidence to justify a New Drug Application (NDA). Still, the management allegedly continued to promote a narrative that the Phase 3 trial results were robust, misrepresenting their potential success.

The situation worsened on December 31, 2025, when Corcept disclosed that it had received a Complete Response Letter (CRL) from the FDA, which indicated that the agency could not find a favorable benefit-risk assessment for relacorilant due to insufficient evidence. This bombshell revelation led to a staggering drop in the company’s stock price, erasing nearly $2.5 billion in market capitalization as shares plummeted from $70.20 to $34.80 overnight.

Investor Implications and Next Steps

For investors who have sustained losses as a result of these developments, now is the critical time to consider their options. Hagens Berman has established a dedicated page for Corcept's case where affected investors can review the allegations and take necessary steps towards litigation. The law firm is urging Corcept shareholders to act promptly to secure their rights before the imminent deadline.

If you believe you have been negatively impacted by the misinformation related to Corcept, consult with legal experts and consider registering as a Lead Plaintiff to potentially recover your losses. Contact Hagens Berman at 844-916-0895 or via email for more personalized assistance regarding the specifics of your investment losses and the options available to you.

The Role of Whistleblowers

In addition to investor claims, Hagens Berman is open to hearing from whistleblowers who may have non-public information regarding Corcept and its operations. Those with insider knowledge could play a crucial role in the ongoing investigation, and under the SEC Whistleblower program, they could be eligible for financial rewards based on the success of any recovery achieved.

About Hagens Berman

Hagens Berman is a well-respected global plaintiffs' rights law firm specializing in complex litigation pertaining to corporate accountability. With a proven track record of securing over $2.9 billion in recoveries for various parties impacted by corporate misconduct, the firm remains a dedicated advocate for investors and whistleblowers alike. For further information or regular updates, you can follow their initiatives at @ClassActionLaw.

As the situation surrounding Corcept continues to develop, stakeholders and interested parties should remain vigilant and informed. This case not only affects investors but also highlights the significance of transparency in corporate communication and drug approval processes.